RT Journal Article
T1 Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
A1 Ramos-Rincon, Jose Manuel
A1 Perez-Belmonte, Luis M
A1 Carrasco-Sanchez, Francisco Javier
A1 Jansen-Chaparro, Sergio
A1 De-Sousa-Baena, Mercedes
A1 Bueno-Fonseca, Jose
A1 Perez-Aguilar, Maria
A1 Arevalo-Cañas, Coral
A1 Bacete-Cebrian, Marta
A1 Mendez-Bailon, Manuel
A1 Fiteni-Mera, Isabel
A1 Gonzalez-Garcia, Andres
A1 Navarro-Romero, Francisco
A1 Tuñon-de-Almeida, Carlota
A1 Muñiz-Nicolas, Gemma
A1 Gonzalez-Noya, Amara
A1 Hernandez-Milian, Almudena
A1 Garcia-Garcia, Gema Maria
A1 Alcala-Pedrajas, Jose Nicolas
A1 Herrero-Garcia, Virginia
A1 Corral-Gudino, Luis
A1 Comas Casanova, Pere
A1 Meijide-Miguez, Hector
A1 Casas-Rojo, Jose Manuel
A1 Gomez-Huelgas, Ricardo
K1 Age ≥ 80
K1 Cardiometabolic therapy
K1 Coronavirus disease-2019
K1 Mortality
K1 Type 2 diabetes
K1 Área Sanitaria Norte de Córdoba
AB The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
PB Oxford University Press
YR 2021
FD 2021-05-04
LK http://hdl.handle.net/10668/17741
UL http://hdl.handle.net/10668/17741
LA en
NO Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109
DS RISalud
RD Apr 10, 2025